Stress-Induced Cardiomyopathy — Takotsubo

• Excessive catecholamine surge: Acute emotional or physical stress triggers sympathetic nervous system hyperactivation, resulting in markedly elevated circulating catecholamines (epinephrine and norepinephrine levels may be 2-3× baseline). In postmenopausal women with reduced estrogen-mediated cardioprotection, this leads to direct myocardial toxicity via β-adrenergic receptor overstimulation, calcium overload, and mitochondrial dysfunction causing acute myocyte necrosis and apoptosis.

• Microvascular dysfunction and coronary vasospasm: Excessive catecholamine stimulation causes paradoxical α-adrenergic-mediated vasoconstriction in coronary microvasculature, resulting in impaired coronary flow reserve and regional myocardial ischemia despite angiographically normal epicardial coronary arteries. Endothelial dysfunction and reduced nitric oxide bioavailability contribute to sustained vasomotor abnormalities.

• Myocardial stunning and metabolic derangement: The combination of catecholamine cardiotoxicity and microvascular ischemia produces acute myocardial stunning without irreversible necrosis. Histology reveals myocyte necrosis, apoptosis, and contraction band necrosis, predominantly in the apex and anterolateral wall. The stunning is reversible because the insult is sublethal in most cases; recovery occurs as catecholamine levels normalize and metabolic homeostasis is restored, typically within 2-4 weeks.

• Estrogen deficiency hypothesis: Postmenopausal status is the strongest demographic risk factor. Loss of estrogen's protective effects on β-adrenergic signaling, combined with increased sensitivity to catecholamines, enhanced oxidative stress, and reduced endothelial-derived vasodilators, creates a milieu predisposing to stress-induced dysfunction.

Demographic factors

• Postmenopausal women (80-90% of cases)
• Age >50 years (mean age 63-65)
• Female predominance (5-10:1 female-to-male ratio)

Emotional stressors

• Death or serious illness of loved ones
• Acute grief or bereavement
• Relationship conflict or breakup ("broken heart syndrome")
• Public speaking or performance anxiety
• Financial loss or legal proceedings

Physical stressors

• Acute medical illness (sepsis, pneumonia, pulmonary embolism, stroke)
• Surgery or anesthesia
• Severe hypertensive episodes
• Strenuous exercise or seizures
• Excessive alcohol or cocaine use

Medical conditions increasing susceptibility

• Hypertension (present in 50-60% of cases)
• Diabetes mellitus
• Chronic kidney disease
• Hypothyroidism
• Neurological disorders (seizures, intracranial hemorrhage, head trauma)
• Malignancy
• Pheochromocytoma (catecholamine-secreting tumor)

Medications

• Sympathomimetic agents (ephedrine, pseudoephedrine, dobutamine)
• Cocaine and amphetamines
• Excessive catecholamine administration

Spontaneous form

• Approximately 5-15% of cases lack identifiable stressor, termed "spontaneous takotsubo," often associated with acute medical illness

• Chest pain: Acute onset, typically substernal, may radiate to arm or jaw, indistinguishable from acute coronary syndrome; present in 70-80% of cases
• Dyspnea: Acute shortness of breath related to acute heart failure; present in 50-70% of cases
• Syncope or presyncope: May occur secondary to arrhythmia or hemodynamic collapse
• Palpitations: Often associated with arrhythmias (particularly atrial fibrillation)

Physical examination findings

• New or accentuated systolic murmur: May reflect acute mitral regurgitation from papillary muscle dysfunction or ventricular remodeling
• Rales or crackles: Bilateral crackles if acute pulmonary edema develops
• Hypotension or hypertension: Acute hypertension (>160/90 mmHg) is common at presentation; hypotension indicates cardiogenic shock
• Tachycardia: Sinus tachycardia typical; atrial fibrillation may develop
• Signs of heart failure: Elevated jugular venous pressure, peripheral edema (if acute decompensation develops)
• S3 gallop: May appear with impaired ventricular function

Atypical presentations

• Some patients present with mild symptoms and are discovered incidentally
• Silent presentations without chest pain occur in 5-10%
• May mimic acute cerebrovascular event with neurogenic ST-segment changes

Electrocardiography (ECG)

• Diffuse ST-segment elevation in precordial and limb leads (mimic acute anterior or anterolateral STEMI)
• T-wave inversions: Typically develop after 24-48 hours, may be diffuse and dramatic
• QT prolongation: Common, may predispose to torsades de pointes
• Absence of reciprocal changes: Unlike typical STEMI, reciprocal ST-segment depression is uncommon or minimal
• Pseudo-Wellens changes (T-wave inversion in precordial leads) may develop

Cardiac biomarkers

• Troponin elevation: Mild-to-moderate elevation (typically <10× upper limit of normal), disproportionately lower than ECG changes and clinical presentation
• CK elevation: Mild elevation (CK-MB fraction <10% of total, unlike STEMI where it may be >15%)
• BNP/NT-proBNP: Marked elevation reflecting acute heart failure
• Lactic acidosis: May develop in cardiogenic shock

Echocardiography (most important imaging)

• Apical ballooning: Characteristic akinesis or dyskinesis of apical and mid-ventricular segments with basal hyperkinesis
• Apical variant (classic): 80-90% of cases, with apical akinesis and basal hyperfunction
• Mid-ventricular variant: 10-15% of cases, with mid-cavity akinesis and preserved apical function
• Basal variant: <5% of cases, rare, with basal akinesis
• Reduced LVEF: Acutely depressed (often 20-40%) at presentation, rapidly recovers
• Dynamic LVOT obstruction: May develop mid-cavity obstruction mimicking hypertrophic cardiomyopathy physiology
• Mitral regurgitation: Often mild-to-moderate, secondary to papillary muscle dysfunction
• No thrombus: Absence of left ventricular thrombus (distinguishes from anterior STEMI)

Coronary angiography

• Normal or non-obstructive coronary arteries: Absence of significant (≥50%) stenosis in any epicardial vessel is virtually required for diagnosis
• Normal coronary flow reserve study (if performed)
• Appearance of "takotsubo" or "octopus pot" on left ventriculography due to apical ballooning with basal hyperkinesis

Diagnostic criteria (modified Mayo Clinic criteria)

1. 1.Transient hypokinesis, akinesis, or dyskinesis of the left ventricular mid-segments with or without apical involvement; regional wall motion abnormality extending beyond a single epicardial vascular distribution
2. 2.Absence of obstructive coronary artery disease or angiographic evidence of acute plaque rupture
3. 3.New electrocardiographic abnormalities (ST elevation or T-wave inversion) or modest elevation in cardiac troponin
4. 4.Absence of recent significant head trauma, intracranial bleeding, pheochromocytoma, myocarditis, or hypertrophic cardiomyopathy

Advanced imaging

• Cardiac magnetic resonance (CMR): May demonstrate subendocardial delayed gadolinium enhancement, differentiates from acute myocarditis; helps identify myocardial necrosis pattern
• Positron emission tomography (PET): May show reduced regional perfusion and metabolism in apical region

Acute phase management

• ACE inhibitors (e.g., lisinopril, enalapril) or angiotensin receptor blockers (losartan, valsartan): First-line agents for acute left ventricular dysfunction; reduce afterload, prevent ventricular remodeling, and promote recovery of systolic function. Initiated at discharge or when blood pressure permits (target systolic BP >90 mmHg).

• Beta-blockers (e.g., metoprolol, carvedilol): Reduce sympathetic drive and catecholamine-induced cardiotoxicity; reduce heart rate and blood pressure, beneficial in hemodynamically stable patients. Avoid or use cautiously in hypotensive patients or those with cardiogenic shock.

• Inotropic support (dobutamine, milrinone): Reserved for patients with hemodynamic compromise, cardiogenic shock, or severe LVOT obstruction; cautiously used as dobutamine (beta-agonist) may theoretically worsen catecholamine toxicity, but clinical benefit typically outweighs risk. Milrinone (phosphodiesterase inhibitor) preferred in some centers as it avoids additional sympathomimetic stimulation.

• Intra-aortic balloon pump (IABP): Consider in refractory cardiogenic shock, particularly when dynamic LVOT obstruction is prominent or in cases complicated by mechanical complications.

• Mechanical circulatory support (Impella, ECMO): Reserved for fulminant cases with refractory shock unresponsive to medical therapy and IABP; rare but life-saving in severe presentations.

Arrhythmia management

• Atrial fibrillation (most common arrhythmia): Rate control with beta-blockers or calcium channel blockers (diltiazem, verapamil) preferred; anticoagulation indicated if AF persists >24-48 hours or if CHA₂DS₂-VASc score warrants it; spontaneous conversion occurs in majority of cases.
• Ventricular arrhythmias and torsades de pointes: Correct hypokalemia and hypomagnesemia; avoid QT-prolonging agents; beta-blockers and magnesium sulfate for acute management; temporary pacing if bradycardia develops.
• Implantable cardioverter-defibrillator (ICD): Not routinely indicated given expected rapid recovery of function; reserve for persistent LVEF <35% at discharge despite optimal medical therapy and documented life-threatening arrhythmias.

Ancillary therapies

• Diuretics (furosemide, bumetanide): For volume overload and pulmonary edema; judicious use as aggressive diuresis may precipitate hypotension.
• Anticoagulation: Consider in patients with severely reduced EF and immobility; short duration of anticoagulation generally sufficient given rapid functional recovery.
• Hydration: May be necessary in dehydrated or shock states; guided by hemodynamic parameters.

Long-term management

• ACE inhibitor/ARB continuation: Continued for 3-6 months; may be discontinued if LVEF normalizes and remains normal on follow-up echocardiography (typically by 6-8 weeks), though some cardiologists continue long-term for cardioprotection.
• Beta-blocker continuation: Generally continued at discharge; can be tapered or discontinued when EF recovers to normal range.
• Aspirin: Typically initiated during acute phase (as for ACS) but can be discontinued once diagnosis confirmed; no evidence of benefit in takotsubo but no clear harm.

Monitoring

• Serial echocardiography: At 1-2 weeks and 6-8 weeks to document functional recovery; most patients show marked improvement by 2-4 weeks.
• Repeat troponin levels: To confirm appropriate decline in biomarkers.
• Telemetry monitoring: Minimum 24-48 hours to detect arrhythmias; extended monitoring if significant arrhythmias develop.
• Stress testing or repeat angiography: Generally not necessary if clinical recovery is evident and coronary anatomy known; consider if atypical clinical course or diagnostic uncertainty persists.

Acute phase complications

• Cardiogenic shock: Occurs in 5-10% of cases, typically in first 24-48 hours; managed with inotropic support, IABP, or mechanical circulatory support; mortality increases substantially but reversible with appropriate support.

• Acute mitral regurgitation: Results from papillary muscle dysfunction or apical ballooning creating geometric distortion; usually mild-to-moderate and resolves with ventricular remodeling; severe regurgitation may require intra-aortic balloon pump or urgent surgical intervention (rare).

• Dynamic left ventricular outflow tract obstruction: Occurs in 10-20% of cases, particularly in mid-ventricular variant; can be severe and hemodynamically significant; distinguished from HCM by dynamic nature and reversibility; paradoxically worsens with vasodilators and positive inotropes (which increase contractility and obstruction); managed with beta-blockers and fluid administration to increase LV volume.

• Ventricular free wall rupture: Rare but catastrophic (0.3% of cases); presents with acute hemodynamic collapse and tamponade; diagnosis by echocardiography (pericardial effusion) or computed tomography; managed emergently with pericardiocentesis and surgical repair; mortality >50% even with intervention.

• Acute ventricular septal defect: Rare complication from septal wall necrosis; presents with new holosystolic murmur and acute decompensation; diagnosis by echocardiography showing left-to-right shunt; may require surgical repair if hemodynamically significant.

• Ventricular thrombus formation: Unusual given acute presentation and normal epicardial arteries; anticoagulation indicated if detected; spontaneous resolution expected with EF recovery.

• Arrhythmias: Atrial fibrillation (most common, 6-25%), ventricular tachycardia, torsades de pointes (related to QT prolongation); majority self-limited and responsive to beta-blockers and electrolyte correction.

Recurrence

• Recurrence rate 1-5% over long-term follow-up; risk factors for recurrence include younger age, female sex, and prior history; repeat episodes follow similar course with complete recovery expected.

Neurological complications

• Neurogenic stunning myocardium: In cases preceded by acute neurological events (stroke, seizure, head trauma); represents overlap between stress cardiomyopathy and neurogenic myocardial injury.

Short-term outcomes

• In-hospital mortality: 1-5% overall; up to 10-20% in cases with cardiogenic shock or mechanical complications
• Functional recovery: Near-complete normalization of LVEF occurs in 90-95% of survivors by 6-8 weeks
• Timeline: Most patients show improvement in symptoms within 1-2 weeks; EF typically normalizes by 4-8 weeks post-presentation

Favorable prognostic factors

• Absence of cardiogenic shock at presentation
• Hemodynamic stability
• Younger age
• Female sex (counterintuitively, associated with better outcome despite higher incidence)
• Absence of mechanical complications
• Rapid resolution of ST-segment changes

Unfavorable prognostic factors

The stem that gives it away

• Postmenopausal woman + acute emotional or physical stressor + chest pain + anterior ST elevation: the classic vignette (broken heart syndrome). Buzzwords to recognize: apical ballooning, octopus pot, transient LV apical akinesis with basal hyperkinesis.
• Troponin–wall motion mismatch: only modest troponin elevation despite a large akinetic territory and dramatic ECG, while BNP/NT-proBNP is markedly elevated. In true anterior STEMI, troponin rise is proportionate to the infarct size.
• Wall motion abnormality crosses coronary territories: a circumferential apical/mid-cavity abnormality that cannot be mapped to the LAD alone is the single most discriminating echo finding (modified Mayo criteria).

Single best next step

• Urgent coronary angiography: the presentation is indistinguishable from ACS, so ACC/AHA acute coronary syndrome guidance drives the initial pathway — activate the cath lab; the diagnosis is made after obstructive CAD and plaque rupture are excluded. Do not "diagnose Takotsubo clinically" and defer catheterization. If the ECG shows a new LBBB, apply Sgarbossa criteria rather than treating LBBB alone as a STEMI equivalent.

The association examiners love

• Catecholamine excess states: pheochromocytoma, subarachnoid hemorrhage/ischemic stroke or seizure (neurogenic stunned myocardium), exogenous sympathomimetics, and cocaine. A stem with sudden severe headache followed by anterior ST elevation is neurogenic stress cardiomyopathy until proven otherwise. Note that pheochromocytoma is a formal exclusion in the modified Mayo criteria.

Distractors to avoid

• Do not give inotropes or nitrates when dynamic LVOT obstruction is present: dobutamine and vasodilators worsen the gradient. Volume and beta-blockade (with a pure alpha agonist such as phenylephrine if pressors are required) are the physiologic answer.
• Do not place an ICD acutely: dysfunction is stunning, not scar, and recovers in weeks; per ACC/AHA/HRS ventricular arrhythmia guidance, device decisions await recovery of a reversible cause.
• Do not choose fibrinolysis on the basis of ST elevation alone in a stem describing a normal angiogram.
• Do not confuse with myocarditis: CMR in Takotsubo lacks the mid-wall/subepicardial late gadolinium enhancement pattern typical of myocarditis.